Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 5/20 | 0.46 |
| ▸ | HPGDS | O60760 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 7/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825074 | 0.90 | HPGDS (0.50) | SSTR3HPGDSKCNH2CYP3A4CYP2C9 | |
| SCHEMBL13145134 | 0.90 | SSTR3 (0.45) | SSTR3HPGDSKCNH2CYP3A4CYP2C9 | |
| SCHEMBL10132326 | 0.90 | SSTR3 (0.45) | SSTR3HPGDSKCNH2CYP3A4CYP2C9 | |
| SCHEMBL825078 | 0.84 | HPGDS (0.47) | SSTR3HPGDSKCNH2CYP3A4CYP2C9 | |
| SCHEMBL825176 | 0.83 | HPGDS (0.46) | SSTR3HPGDSKCNH2CYP3A4CYP2C9 | |
| SCHEMBL12147941 | 0.82 | SSTR3 (0.42) | SSTR3HPGDSKCNH2CYP3A4CYP2C9 | |
| SCHEMBL1316015 | 0.79 | HPGDS (0.41) | SSTR3HPGDSKCNH2CYP3A4CYP2C9 | |
| SCHEMBL1316017 | 0.79 | HPGDS (0.41) | SSTR3HPGDSKCNH2CYP3A4CYP2C9 | |
| SCHEMBL1316016 | 0.79 | HPGDS (0.41) | SSTR3HPGDSKCNH2CYP3A4CYP2C9 | |
| SCHEMBL1293625 | 0.77 | SSTR3 (0.39) | SSTR3HPGDSKCNH2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143301-B2 | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | SSTR3 4672/4885HPGDS 582/4885KCNH2 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.